What is Choice Genetics?
Choice Genetics operates as a premier global swine genetics enterprise, functioning under the umbrella of Groupe Grimaud, the world's second-largest multi-species animal genetics firm. By leveraging a sophisticated innovation platform, the company focuses on the development of superior breeding stock, including the CG32 and NAMA parent gilts, alongside the EBX and P88 terminal sires. Their market strategy centers on value-driven innovation, utilizing unique phenotypic traits to enhance the accuracy of Estimated Breeding Values (EBVs). With a robust operational footprint spanning four continents and subsidiaries in key agricultural hubs such as Brazil, Canada, China, and the United States, Choice Genetics provides essential genetic solutions to pork producers in over 25 countries, prioritizing efficiency, performance, and long-term industry sustainability.
How much funding has Choice Genetics raised?
Choice Genetics has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Choice Genetics
PPP
Public-Private Partnership
What's next for Choice Genetics?
Following this substantial financing, Choice Genetics is poised to deepen its commitment to cutting-edge R&D, aiming to outpace competitors in the rate of genetic advancement. The strategic allocation of these funds will likely focus on scaling its proprietary breeding technologies and expanding its reach in emerging markets where demand for high-performance swine genetics is rising. By maintaining its focus on phenotypic precision and total commercial value, the company is set to solidify its leadership in the animal biotechnology space, navigating the complexities of global food security while delivering consistent value to its international client base.
See full Choice Genetics company page
